A carregar...
Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer
Human epidermal growth factor 2 (HER2) is overexpressed in 15–20% of breast carcinomas. The overexpression of HER2 was previously associated with a poor prognosis until the development of the first anti-HER2 therapy, trastuzumab, which drastically improves the prognosis of HER2-overexpressing breast...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4998521/ https://ncbi.nlm.nih.gov/pubmed/27602133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2016.4891 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|